EUVIMEDEUVIMED entdecken
Crossref

Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database

Binod Dhakal, Jinghua He, Jordan M Schecter, William Deraedt, Ana Slaughter, Carolina Lonardi, Sandhya Nair, Jianming He, Seina Lee, Patricia Cost, Nitin Patel, Mythili Koneru und 1 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.01.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Binod Dhakal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: bdhakal@mcw.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: J&J Innovative Medicine, National Cancer Institute, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Early continuous lenalidomide use for multiple myeloma (MM) treatment has led to more patients with lenalidomide-refractory disease at earlier lines of therapy (LOTs). Real-world treatment practices and outcomes in elderly patients with comorbidities are not well characterized. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, we analyzed data from patients who were diagnosed with MM between 2014 and 2019, had 1 to 3 prior LOTs, including a proteasome inhibitor and an immunomodulatory drug, and were lenalidomide refractory. Patients were followed from index (initiation of first subsequent LOT after meeting eligibility criteria and after January 1, 2016) until death, end of continuous Medicare enrollment, or December 31, 2020. RESULTS: This analysis included 1297 patients (median age, 75 years). The mean National Cancer Institute Comorbidity Index score was 0.87 and 81% had at least 1 comorbidity. Singlet, doublet, and triplet therapies each accounted for ∼30% of index regimens. The most common regimens, ± corticosteroid, were daratumumab-pomalidomide (15%), pomalidomide (13%), and daratumumab (12%). Median overall survival and time to next treatment (TTNT) were 29.3 and 8.5 months, respectively. TTNT decreased with successive LOTs (1 prior LOT, 11.0 months; 3 prior LOTs, 6.1 months). CONCLUSION: Elderly patients with comorbidities and lenalidomide-refractory disease after 1 to 3 LOTs receive suboptimal regimens, have poor outcomes, and move rapidly through treatments, highlighting the need for new effective treatments for this difficult-to-treat population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLenalidomideAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmHumansAgedMaleFemaleSEER ProgramUnited StatesMedicareAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

ComorbiditiesElderly patientsReal-world survivalReal-world time to next treatment

Substanzen

Lenalidomide

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: bdhakal@mcw.edu.
  • Johnson & Johnson, Titusville, NJ. Electronic address: Jhe31@its.jnj.com.
  • Johnson & Johnson, Raritan, NJ. Electronic address: jschecte@its.jnj.com.
  • Johnson & Johnson, Beerse, Belgium. Electronic address: wderaedt@its.jnj.com.
  • Johnson & Johnson, Zug, Switzerland. Electronic address: aslaught@its.jnj.com.
  • Johnson & Johnson, Buenos Aires, Argentina. Electronic address: clonardi@its.jnj.com.

Förderung

  • J&J Innovative Medicine
  • National Cancer Institute
  • Centers for Disease Control and Prevention
  • Georgia Department of Public Health
  • Legend Biotech
  • University of Southern California
  • Johnson & Johnson Innovative Medicine

Zitieren

APA

Dhakal, B., He, J., Schecter, J. M., Deraedt, W., Slaughter, A., Lonardi, C., Nair, S., He, J., Lee, S., Cost, P., Patel, N., Koneru, M., & Einsele, H. (2025). Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.01.009

Vancouver

Dhakal B, He J, Schecter JM, Deraedt W, Slaughter A, Lonardi C, et al. Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.01.009

BibTeX
@article{Dhakal2025,
  author = {Dhakal, Binod and He, Jinghua and Schecter, Jordan M and Deraedt, William and Slaughter, Ana and Lonardi, Carolina and Nair, Sandhya and He, Jianming and Lee, Seina and Cost, Patricia and Patel, Nitin and Koneru, Mythili and Einsele, Hermann},
  title = {Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.01.009}
}
Kostenlos starten →